Bibliography
- STEELE P: Merck & Co.: updated analysis of patenting with comparative data for thirty-five companies. Expert Opin. Ther. Patents (1997) 7(8):795–799.
- ••Provides the comparison analysis for thepreceding period.
- BURKE JF, THOMAS SM, BRADY M: Merck: the scattering of DNA sequence patents. Expert Opin. Ther. Patents (1997) 7(2):1393–1400.
- •Indicates Merck's limited activity in gene patenting.
- STEELE P: Drug patenting in 2001. Expert Opin. Ther: Patents(2002) 12(1):3–10.
- •Useful overview of all the major companies' activities in 2001.
- NORMAN P: Pfizer, Inc.: analysis of patenting 1998–2001. Expert Opin. Ther. Patents (2002) 12(5):725–732.
- NORMAN P: GlaxoSmithKline Plc: analysis of patenting 1998-2001. Expert Opin. Ther: Patents (2002) 12(9):1407–1415.
- NORMAN P: Merck & Co. In: Pharmaceutical Development Pipelines, the top 10 companies (Chapter SMi Publishing, UK (2002).
- NORMAN P: Merck & Co. In: Early-Stage Pharmaceutical Development Pipelines, The Top 20 Companies (Chapter 12). SMi Publishing, UK (2002).
- •Useful comparison highlighting how little is known about Merck's early stage pipeline.
- CLAIBORNE CE McCAULEY JA, LIBBY BE et al.: Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett (2003) 13(4):697–700.
- Current Patents: Drug patents 2001, a review of pharmaceutical patenting 1995–2001. Current Patents Ltd, London, UK (2001).
- WILLIAMS TM: Inhibitors of protein farnesylation 1998. Expert Opin. Ther. Patents (1998) 8(5):553–569.
- WILLIAMS TM: Inhibitors of protein prenylation 1999. Expert Opin. Ther. Patents (1999) 9(9):1263–1280.
- MACH WATE M, HARADA S, LEU CT: Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. MM. PharmacoL (2001) 60(1):36–41.
- SPENCE S, VETTER C, HAGMANN WK et al.: Effects of VLA-4 antagonists in rat whole embryo culture. Teratology (2002) 65(1):26–37.